5 innovadores medicamentos chinos, incluyendo inhibidores de:
🧬 KRAS G12C
🧬 EGFR de tercera generación
🧬 EGFR exon 20

#Fulzerasib #Sunvozertinib #Limertinib #Glecirasib #Garsorasib #Cáncer #Oncología #TerapiaDirigida #InnovaciónMédica #KRAS
#KRASG12C #EGFR #EGFRexon20 #DengYueMedicinasEnHongKong

FDA Approves Sunvozertinib for EGFR Exon 20 NSCLC Sunvozertinib, developed by Dizal Pharmaceuticals, receives FDA accelerated approval for metastatic NSCLC with EGFR exon 20 mutations.

FDA Grants Accelerated Approval to Sunvozertinib for EGFR Exon 20 Insertion Mutations in NSCLC
@fda.gov

oncodaily.com/oncolibrary/...

#OncoDaily #Oncology #Cancer #Health #Medicine #MedEd #MedOnc #MedNews #FDA #Sunvozertinib #NSCLC #LungCancer

Dizal Achieves Major Milestone in NSCLC Treatment with Sunvozertinib Clinical Trial Enrollment Completion Dizal successfully completes enrollment for WU-KONG28 trial, evaluating sunvozertinib for NSCLC patients with specific genetic mutations, marking a significant step forward in cancer treatment.

Dizal Achieves Major Milestone in NSCLC Treatment with Sunvozertinib Clinical Trial Enrollment Completion #China #Shanghai #NSCLC #Dizal #Sunvozertinib

Dizal's Sunvozertinib Receives FDA Priority Review as a New Treatment for NSCLC Dizal's new drug application for Sunvozertinib has received priority review by the FDA, marking a significant step for NSCLC treatment options.

Dizal's Sunvozertinib Receives FDA Priority Review as a New Treatment for NSCLC #Shanghai #USA #FDA #Dizal #Sunvozertinib

Dizal Unveils Promising Data for Sunvozertinib Against Resistant Lung Cancer Dizal shares positive pooled data on sunvozertinib, showcasing its effectiveness in treating non-small cell lung cancer resistant to EGFR inhibitors.

Dizal Unveils Promising Data for Sunvozertinib Against Resistant Lung Cancer #China #Shanghai #NSCLC #Dizal #Sunvozertinib